Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”.

Be sure to check it out!
Read here on Onctotarget